Skip to main content Skip to main menu
UF Health University of Florida

College of Pharmacy

UNIVERSITY of FLORIDA

Apply to pharm.d. program
Julie A Johnson

Julie A Johnson Pharm.D.

Dean & Distinguished Professor

Department: Dean's Office
Business Phone: (352) 273-6309
Business Email: julie.johnson@ufl.edu
CV: View Curriculum Vitae

About Julie A Johnson

Julie A. Johnson, Pharm.D., is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/pharmacokinetics at Ohio State.

Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. She is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 290 peer reviewed publications and nearly $45 million in research funding as principal investigator. In 2015, 2016, 2017 she was named a Thomson Reuters (now Clarivate Analytics) Highly Cited Scientist in Pharmacology and Toxicology, and in 2018 in the Cross Discipline category, indicating she is in the top 1% of the most highly cited scientists in the field globally.

Johnson has served on the Nonprescription Drugs Advisory Committee of the FDA, the XNDA Study Section at NIH, and in numerous scientific capacities with NIH’s NHLBI. She has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology (ACCP-Pharmacology). Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including teaching awards from both the University of Tennessee (1996) and the University of Florida (2001); the Ohio State University Alumni Association William Oxley Thompson Award for early career achievement (1997), Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award (2009) and Russell R Miller Award for Contributions to the Literature (2010), both from ACCP, the Southeastern Universities Research Association Distinguished Scientist Award (2015); AACP Volwiler Research Achievement Award (2016), the ACCP-Pharmacology Distinguished Scientist Award (2019), and ACCP Paul Parker Medal (2019), among others.

Honors & Awards

Volwiler Research Achievement Award
2016 · American Association of Colleges of Pharmacy
Highly Cited Scientist
2015-2018 · Clarivate Analytics
Distinguished Scientist Award
2015 · Southeastern Universities Research Associate
Elected Member
2014 · National Academy of Medicine
Honorary Fellow Award
2014 · American College of Clinical Pharmacology
Russell Miller Award for Contribution to the Literature
2010 · American College of Clinical Pharmacy
Therapeutic Frontiers Award
2009 · American College of Clinical Pharmacy
Fellow
2009 · American Heart Association; Functional Genomics and Translational Biology Council
Paul Dawson Biotechnology Research Award
2007 · American Association of Colleges of Pharmacy
Leon I. Goldberg Young Investigator Award
2004 · American Society for Clinical Pharmacology and Therapeutics
William Oxley Thompson Alumni Award
1997 · The Ohio State University
Fellow
1996 · American College of Clinical Pharmacy

Publications

2019
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies
European Journal of Pharmaceutical Sciences
2019
CYP2D6-guided Opioid Therapy Improves Pain Control in CYP2D6 Intermediate and Poor Metabolizers: A Pragramatic Clinical Trial
Genetics in medicine : official journal of the American College of Medical Genetics
2018
Genome-wide association analysis of common genetic variants of resistant hypertension.
The Pharmacogenomics Journal
2018
Clinical Implementation of Rapid Cyp2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Intervention
2018
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
Clinical Pharmacology & Therapeutics
2018
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine
Public Health Genomics
2018
Multisite Investigation of Strategies for the Implementation of Cyp2C19 Genotype-Guided Antiplatelet Therapy
Clinical Pharmacology & Therapeutics
2018
Proton Pump Inhibitors: From Cyp2C19 Pharmacogenetics to Precision Medicine
Expert Opinion on Drug Metabolism & Toxicology
2018
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Pharmacogenetics and genomics
2018
Blood Pressure Signature Genes and Blood Pressure Response to Thiazide Diuretics: Results From the Pear and Pear-2 Studies
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the Pear Study (Pharmacogenomic Evaluation of Antihypertensive Responses)
Circulation-Genomic and Precision Medicine
2017
Institutional Profile: University of Florida Health Personalized Medicine Program
Pharmacogenomics
2017
Genetic Variation at 16Q24.2 Is Associated With Small Vessel Stroke
Annals of Neurology
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response
Circulation-Cardiovascular Genetics
2017
Genome-Wide Study of Resistant Hypertension Identified From Electronic Health Records
PLOS One
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/Beta-Blocker Combination Therapy in the Pear (Pharmacogenomic Evaluation of Antihypertensive Responses) and Invest (International Verapamil-Senior Trandolapril Study) Trials
2017
Relations Between Lipoprotein(A) Concentrations, Lpa Genetic Variants, and the Risk of Mortality in Patients With Established Coronary Heart Disease: a Molecular and Genetic Association Study
Lancet Diabetes and Endocrinology
2017
Blood Pressure Response to Metoprolol and Chlorthalidone in European and African Americans With Hypertension
Journal of Clinical Hypertension
2017
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide
Hypertension
2017
Pharmacogenetic Associations of Beta 1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the Sps3 Trial (Secondary Prevention of Small Subcortical Strokes)
Stroke
2017
Fifteen New Risk Loci for Coronary Artery Disease Highlight Arterial-Wall-Specific Mechanisms
Nature Genetics
2016
Identification of Additional Risk Loci for Stroke and Small Vessel Disease: A Meta-Analysis of Genome Wide Association Studies
Lancet Neurology
2016
Use of Personal Genotype Data in Pharmacy Education: Effects on Student Learning and Attitudes in a Pharmacogenomics Course
American Journal of Pharmaceutical Education
2016
Impact of GGCX, STX1B, and FPGS Polymorphisms on Warfarin Dose Requirements in European Americans and Egyptians
Clinical and Translational Science
2016
Presence of Arachidonoyl-Carnitine Is Associated With Adverse Cardiometabolic Responses in Hypertensive Patients Treated With Atenolol
2016
Novel Plasma Biomarker of Atenolol-Induced Hyperglycemia Identified Through a Metabolomics-Genomics Integrative Approach
2016
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension
American Journal of Hypertension
2016
CYP2C19 and CES1 Polymorphisms and Efficacy of Clopidogrel and Aspirin Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease
Journal of Neurosurgery
2016
Genetic and Non-Genetic Factors Affecting Clopidogrel Efficacy in Egyptian Population
Clinical and Translational Science
2016
Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation- Is There a Correlation?
Clinical and Translational Science
2016
Population-Specific Single Nucleotide Polymorphism Confers Increased Risk of Venous Thromboembolism in African Americans
Molecular Genetics and Genomic Medicine
2016
Identification of Suitable Endogenous Normalizers for qRT- PCR Analysis of Plasma microRNA Expression in Essential Hypertension
Molecular Biotechnology
2016
The Ignite Network: a Model for Genomic Medicine Implementation and Research
2016
Mechanisms and Pharmacogenetics Signals Underlying Thiazide Diuretics Blood Pressure Response
Current Opinion in Pharmacology
2016
Ces1P1 Variant-816a > C Is Not Associated With Hepatic Carboxylesterase 1 Expression and Activity or Antihypertensive Effect of Trandolapril
2016
A Genetic Response Score for Hydrochlorothiazide Use Insights From Genomics and Metabolomics Integration
Hypertension
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to Beta-Blockers in Hypertensive African Americans
Hypertension
2015
Floppy Mitral Valve/Mitral Valve Prolapse Syndrome:  Beta-Adrenergic Receptor Polymorphism May Contribute to the Pathogenesis of Symptoms
Journal of Cardiology
2015
PTPRD Gene Associated with Blood Pressure Response to Atenolol and Resistant Hypertension in Hypertensive Individuals
Journal of Hypertension
2015
CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study
2015
Genome-Wide Association Study of Warfarin Maintenance Dose in a Brazilian Sample
Pharmacogenomics
2015
Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes
2015
A Genome-Wide Association Study of Ischemic Stroke and its Subtypes Identifies a Novel Locus Near TSPAN2 for Stroke Related to Atherosclerosis
Lancet Neurology
2015
Pharmacogenomics of Hypertension: a Genome-Wide, Placebo-Controlled Cross-Over Study, Using Four Classes of Antihypertensive Drugs
2015
Tet2 and Csmd1 Genes Affect Sbp Response To Hydrochlorothiazide in Never-Treated Essential Hypertensives
Journal of Hypertension
2015
Transethnic Meta Analyses Suggests Genetic Variation in the HEME Pathway Influences Potassium Response in Patients Treated with Hydrochlorothiazide
The Pharmacogenomics Journal
2015
Future Translational Applications from the Contemporary Genomics Era: A Scientific Statement from the American Heart Association
2015
Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics
2015
Loss of Heterozygosity At the Cyp2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies
2015
Warfarin Pharmacogenetics
Trends in Cardiovascular Medicine
2015
Association of Branched and Aromatic Amino Acids Levels With Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients
Metabolic Syndrome and Related Disorders
2015
Floppy mitral valve/mitral valve prolapse syndrome: Beta-adrenergic receptor polymorphism may contribute to the pathogenesis of symptoms
Journal of Cardiology
2014
Baseline Predictors of Central Aortic Blood Pressure: a Pear Substudy
Journal of the American Society of Hypertension
2014
Predictors for Glucose Change in Hypertensive Participants Following Short-Term Treatment with Atenolol or Hydrochlorothiazide
Pharmacotherapy
2014
Alteration in Fasting Glucose After Prolonged Treatment With a Thiazide Diuretic
Diabetes Research and Clinical Practice
2014
Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics
Pharmacotherapy
2014
Gene-Centric Meta-Analyses for Central Adiposity Traits in Up To 57 412 Individuals of European Descent Confirm Known Loci and Reveal Several Novel Associations
Human Molecular Genetics
2014
Is a Diabetes Mellitus-Linked Amino Acid Signature Associated with Beta Blocker-Induced Impaired Fasting Glucose?
Circulation-Cardiovascular Genetics
2014
Cyp2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Pharmacotherapy
2014
Gene-Centric Meta-Analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood Pressure Related Loci
2014
Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients with Essential Hypertension
American Journal of Hypertension
2014
Genome-Wide Association Analyses Suggest Nell1 Influences Adverse Metabolic Response to HCTZ in African-Americans
The Pharmacogenomics Journal
2014
Genetic Variant in Folate Homeostasis Is Associated With Lower Warfarin Dose in African Americans
Blood
2014
Large-Scale Gene-Centric Analysis Identifies Polymorphisms for Resistant Hypertension
2014
PROX1 Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment
Pharmacotherapy
2014
Warfarin Pharmacogenetics: An Illustration of the Importance of Studies in Minority Populations
Clinical Pharmacology & Therapeutics
2014
A Novel Simple Method for Determining Cyp2D6 Gene Copy Number and Identifying Allele(S) With Duplication/Multiplication.
Clinical Pharmacology & Therapeutics
2014
Genetic Influence On Exercise-Induced Changes in Physical Function Among Mobility-Limited Older Adults
Physiological Genomics
2014
Hydrochlorothiazide-Induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study
2014
The Influence of the Cyp2C19{*}10 Allele On Clopidogrel Activation and Cyp2C19(Star)2 Genotyping
Pharmacogenetics and Genomics
2014
Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate
Clinical Pharmacology & Therapeutics
2014
Clinical Pharmacogenetics Implementation: Approaches, Successes, and Challenges
American Journal of Medical Genetics. Part C: Seminars in Medical Genetics
2013
Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations: Finding Signal Within the Noise
Clinical Pharmacology & Therapeutics
2013
Atenolol Induced Hdl-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
PLOS One
2013
Association of Variants in Nedd4L With Blood Pressure Response and Adverse Cardiovascular Outcomes in Hypertensive Patients Treated With Thiazide Diuretics
Journal of Hypertension
2013
University of Florida and Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics.
Pharmacogenomics
2013
Stroke Genetics Network (Sign) Study Design and Rationale for a Genome-Wide Association Study of Ischemic Stroke Subtypes
Stroke
2013
Impact of Tcf7L2 Single Nucleotide Polymorphisms On Hydrochlorothiazide-Induced Diabetes
Pharmacogenetics and Genomics
2013
Genetic Variation in Pear1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes
Circulation-Cardiovascular Genetics
2013
Beta-Adrenergic Receptor Polymorphisms: A Basis for Pharmacogenetics
World Journal of Cardiovascular Diseases
2013
VKORC1 Asp36Tyr Geographic Distribution and its Impact on Warfarin Dose Requirement in Egyptians
Thrombosis and Haemostasis
2013
Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: A Scientific Statement from the American Heart Association
2013
Rationale and Design of the Clarification of Optimal Anticoagulation Through Genetics Trial
American Heart Journal
2013
Lack of Association of the Hmga1 Ivs5-13Insc Variant With Type 2 Diabetes in An Ethnically Diverse Hypertensive Case Control Cohort
2013
Clinical Pharmacogenetics Implementation Consortium (CIPIC) Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Clinical Pharmacology & Therapeutics
2013
The Pharmacogenomics Research Network Translational Pharmacogenetics Program (TPP): Overcoming Challenges of Real-World Implementation
Clinical Pharmacology & Therapeutics
2013
Pharmacogenetics and Cardiovascular Disease-Implications for Personalized Medicine
Pharmacological reviews
2013
Loci Influencing Blood Pressure Identified Using a Cardiovascular Gene-Centric Array
Human Molecular Genetics
2013
Pharmacometabolomics Reveals Racial Differences in Response To Atenolol Treatment
PLOS One
2013
Association of Chromosome 12 Locus With Antihypertensive Response To Hydrochlorothiazide May Involve Differential Yeats4 Expression
Pharmacogenomics Journal
2013
Association Between the Chromosome 9P21 Locus and Angiographic Coronary Artery Disease Burden a Collaborative Meta-Analysis
2013
Impact of Genetic Polymorphisms of Slc2A2, Slc2A5, and Khk On Metabolic Phenotypes in Hypertensive Individuals
PLOS One
2013
Clinical Implementation of Pharmacogenetics: More Than One Gene At a Time
Clinical Pharmacology & Therapeutics
2013
Genomic Association Analysis of Common Variants Influencing Antihypertensive Response To Hydrochlorothiazide
Hypertension
2013
Institutional Profile: University of Florida & Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics
Pharmacogenomics
2013
Pharmacogenomic Association of Nonsynonymous Snps in Siglec12, A1Bg, and the Selectin Region and Cardiovascular Outcomes
Hypertension
2013
A Pharmacogenetic Versus a Clinical Algorithm for Warfarin Dosing
New England Journal of Medicine
2013
Clopidogrel and Warfarin Pharmacogenetic Tests: What Is the Evidence for Use in Clinical Practice?
Current Opinion in Cardiology
2013
Association of Kcnj1 Variation With Change in Fasting Glucose and New Onset Diabetes During Hctz Treatment
Pharmacogenomics Journal
2013
Pharmacogenomic Association of Non-Synonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes
Hypertension
2013
Development of a Novel Pgy2 Pharmacogenomics and Drug Information Residency in a Personalized Medicine Program
Pharmacotherapy
2013
Gene-Centric Meta-Analyses of 108,912 Individuals Confirm Known Body Mass Index Loci and Reveal Three Novel Signals
Human Molecular Genetics
2013
Pharmacogenetics in Clinical Practice: How Far Have We Come and Where Are We Going?
Pharmacogenomics
2013
Pathway Analysis of Genome-Wide Data Improves Warfarin Dose Prediction
Bmc Genomics
2013
Genetic Variants Associated With Warfarin Dose in African-American Individuals: a Genome-Wide Association Study
Lancet
2012
Alpha Adducin-1 (Add1)Singlenucleotide Polymorphism (Snp) Associated With New Onset Diabetes Risk With Hydrochlorothiazide (Hctz) Therapy in the International Verapamil Sr Trandolapril Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics
2012
Academia At the Crossroads: Education and Training in Pharmacogenomics
Personalized Medicine
2012
Genetics and Cardiovascular Disease: A Policy Statement from the American Heart Association
2012
Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol
American Journal of Hypertension
2012
Urate Transporter Gene Slc22A12 Polymorphisms Associated With Obesity and Metabolic Syndrome in Caucasians With Hypertension
Kidney & Blood Pressure Research
2012
Warfarin Pharmacogenetics a Rising Tide for Its Clinical Value
2012
Effects of Genetic Variation in H3K79 Methylation Regulatory Genes On Clinical Blood Pressure and Blood Pressure Response To Hydrochlorothiazide
2012
Advancing Management of Hypertension Through Pharmacogenomics
Annals of Medicine
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics
2012
Academia at the crossroads: education and training in pharmacogenomics.
Personalized Medicine
2012
Effects of High-Fructose Corn Syrup and Sucrose On the Pharmacokinetics of Fructose and Acute Metabolic and Hemodynamic Responses in Healthy Subjects
Metabolism-Clinical and Experimental
2012
Comparing Marginal Structural Models To Standard Methods for Estimating Treatment Effects of Antihypertensive Combination Therapy
Bmc Medical Research Methodology
2012
Impact of the Cyp4F2 P.V433M Polymorphism On Coumarin Dose Requirement: Systematic Review and Meta-Analysis
Clinical Pharmacology & Therapeutics
2012
Power To Identify a Genetic Predictor of Antihypertensive Drug Response Using Different Methods To Measure Blood Pressure Response
2012
Cholesteryl Ester Transfer Protein (Cetp) Polymorphisms Affect Mrna Splicing, Hdl Levels, and Sex-Dependent Cardiovascular Risk
PLOS One
2012
Clinical Predictors of Dysglycemic Effects Associated With Use of Beta Blockers and Thiazide Diuretics
Clinical Pharmacology & Therapeutics
2012
Cyp2C9 Promoter Variable Number Tandem Repeat Polymorphism Regulates Mrna Expression in Human Livers
2012
Large-Scale Gene-Centric Meta-Analysis Across 39 Studies Identifies Type 2 Diabetes Loci
2012
Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose
Clinical Pharmacology & Therapeutics
2012
Large-Scale Gene-Centric Meta-Analysis Across 32 Studies Identifies Multiple Lipid Loci
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics
2012
G Protein Receptor Kinase 4 Polymorphisms Beta-Blocker Pharmacogenetics and Treatment-Related Outcomes in Hypertension
Hypertension
2012
Clopidogrel: a Case for Indication-Specific Pharmacogenetics
Clinical Pharmacology & Therapeutics
2012
Non-Synonymous Snps in Sele, Selp, and Siglec12 Associate With Cardiovascular (Cv) Outcomes in the International Verapamil Sr-Trandol-April Study Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics
2012
Human Polymorphisms in the Glutathione Transferase Zeta 1/Maleylacetoacetate Isomerase Gene Influence the Toxicokinetics of Dichloroacetate
2012
Hypertension Susceptibility Loci and Blood Pressure Response To Antihypertensives Results From the Pharmacogenomic Evaluation of Antihypertensive Responses Study
Circulation-Cardiovascular Genetics
2012
Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
Clinical Pharmacology & Therapeutics
2011
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions
Clinical Pharmacology & Therapeutics
2011
Effects of High Fructose Corn Syrup and Sucrose on the Pharmacokinetics of Fructose and Acute Metabolic and Hemodynamic Responses in Healthy Subjects
Metabolism
2011
Effect of Cytochrome P450 3A5 Genotype On Atorvastatin Pharmacokinetics and Its Interaction With Clarithromycin
Pharmacotherapy
2011
Liver X Receptor a Gene Polymorphisms and Variable Cardiovascular Outcomes in Patients Treated With Antihypertensive Therapy: Results From the Invest-Genes Study
Pharmacogenetics and Genomics
2011
Genome Sequences of Mycoplasma Alligatoris A21Jp2(T) and Mycoplasma Crocodyli Mp145(T)
Journal of Bacteriology
2011
Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease
Circulation-Cardiovascular Genetics
2011
Meta-Analysis of Dense Gene-Centric Association Studies Reveals Common and Uncommon Variants Associated with Height
2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
Clinical Pharmacology & Therapeutics
2011
Response To Letter Regarding Article "Chromosome 9P21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease"
Circulation-Cardiovascular Genetics
2011
Pharmacogenomics: Application to the Management of Cardiovascular Disease
Clinical Pharmacology & Therapeutics
2011
Cardiovascular Pharmacogenomics
2011
Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular/Vascular Coupling: a Comparison With Atenolol (Central Study)
Journal of Clinical Hypertension
2011
Polymorphisms in Genes Coding for Grk2 and Grk5 and Response Differences in Antihypertensive-Treated Patients
Pharmacogenetics and Genomics
2011
Genetic Warfarin Dosing Tables Versus Algorithms
2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
Clinical Pharmacology & Therapeutics
2011
Heart Failure Pharmacogenetics: Past, Present and Future
Current Cardiology Reports
2011
Genetic and Nongenetic Factors Associated With Warfarin Dose Requirements in Egyptian Patients
Pharmacogenetics and Genomics
2011
University of Florida Clinical and Translational Science Institute: Transformation and Translation in Personalized Medicine
Cts-Clinical and Translational Science
2010
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
Clinical Pharmacology & Therapeutics
2010
Study of Vkorc1, Cyp2C9, and Cyp4F2 Polymorphisms and Their Association With Warfarin Dose Requirements in Egyptian Patients.
2010
Very Important Pharmacogene Summary Adrb2
Pharmacogenetics and Genomics
2010
Pharmacogenomics of Antihypertensive Drugs: Past, Present and Future
Pharmacogenomics
2010
Atenolol Exposure and Risk for Development of Adverse Metabolic Effects: a Pilot Study
Pharmacotherapy
2010
Aromatase Gene Polymorphisms Are Associated With Survival Among Patients With Cardiovascular Disease in a Sex-Specific Manner
PLOS One
2010
Impact of Abdominal Obesity On Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications
Hypertension
2010
Warfarin Pharmacogenetics: a Single Vkorc1 Polymorphism Is Predictive of Dose Across 3 Racial Groups
Blood
2010
Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response To Atenolol and Hydrochlorthiazide
Journal of Clinical Hypertension
2010
Statistical Design of Personalized Medicine Interventions: the Clarification of Optimal Anticoagulation Through Genetics (Coag) Trial
Trials
2010
Association Between Melatonin Receptor 1B Single Nucleotide Polymorphisms (Snps) and Response To Antihypertensive Drugs.
Clinical Pharmacology & Therapeutics
2010
Pharmacogenomics of antihypertensive drugs: past, present and future.
Pharmacogenomics
2010
Genetic Variation in the Beta 2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the International Verapamil Sr-Trandolapril Study Genetic Substudy (Invest-Genes)
Circulation-Cardiovascular Genetics
2010
Lack of Association Between Polymorphisms in STK39, a Putative Thiazide Response Gene, and Blood Pressure Response to Hydrochlorothiazide
Pharmacogenetics and Genomics
2010
Plasma Renin Activity Predicts Blood Pressure Responses To Beta-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension
American Journal of Hypertension
2010
Beta-Blocker Pharmacogenetics in Heart Failure
Heart Failure Reviews
2009
Long-Term Mortality Associated With New Onset Diabetes in Hypertensive Cad Patients Following Exposure To Antihypertensive Medications: Findings From the International Verapamail Sr-Trandolapril Study (Invest)
2009
Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order
Clinical Pharmacology & Therapeutics
2009
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension
2009
Altered Beta-2 Adrenergic Receptor Gene Expression in Human Clinical Hypertension
Biological Research for Nursing
2009
Promoter Polymorphisms in Ace (Angiotensin I-Converting Enzyme) Associated With Clinical Outcomes in Hypertension
Clinical Pharmacology & Therapeutics
2009
Warfarin Pharmacogenetics Reply
New England Journal of Medicine
2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Clinical Pharmacology & Therapeutics
2009
Genetic and Pharmacogenetic Associations Between Nos3 Polymorphisms, Blood Pressure, and Cardiovascular Events in Hypertension
American Journal of Hypertension
2009
Role of Carboxylesterase 1 and Impact of Natural Genetic Variants On the Hydrolysis of Trandolapril
2009
Data Trends and Results From An Hlb Testing Laboratory That Has Processed Over 64,000 Commercial and Research Samples Over a Two Year Period in Florida
Phytopathology
2009
Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
American Heart Journal
2009
Genotyping the Gggcgg Tandem Repeat Promoter Polymorphism in the 5-Lipoxygenase Enzyme Gene (Alox5) By Pyrosequencing Assay
Genetic Testing and Molecular Biomarkers
2009
Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
Pharmacotherapy
2009
Estimation of the Warfarin Dose With Clinical and Pharmacogenetic Data
New England Journal of Medicine
2009
Cxcl5/Ena-78 Genotype and Progression To Death Or Transplantation in Heart Failure Patients.
Clinical Pharmacology & Therapeutics
2009
Cacna1C Gene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response
Circulation-Cardiovascular Genetics
2009
Systolic Blood Pressure and Subjective Well-Being in Patients With Coronary Artery Disease
Clinical Cardiology
2008
A Polymorphism in the Nppa Gene Associates With Asthma
Clinical and Experimental Allergy
2008
B1-Adrenergic Receptor Polymorphism Predicts Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Artery Disease
2008
Opinion – Creating and Evaluating Genetic Tests Predictive of Drug Response
Nature reviews. Drug discovery
2008
Vkorc1 and Cyp2C9 Polymorphisms Are Associated With Warfarin Dose Requirements in Turkish Patients
2008
Beta-Adrenergic Receptor Gene Polymorphisms and Beta-Blocker Treatment Outcomes in Hypertension
Clinical Pharmacology & Therapeutics
2008
Regulatory Polymorphism in Vitamin K Epoxide Reductase Complex Subunit 1 (Vkorc1) Affects Gene Expression and Warfarin Dose Requirement
Blood
2008
Beta-Adrenergic Receptor Gene Polymorphisms and Hemodynamic Response To Dobutamine During Dobutamine Stress Echocardiography
Pharmacogenomics Journal
2008
Two Ces1 Gene Mutations Lead To Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis
2008
Alpha-Adducin Polymorphism Associated With Increased Risk of Adverse Cardiovascular Outcomes: Results From Genetic Substudy of the International Verapamil Sr-Trandolapril Study (Invest-Genes)
American Heart Journal
2008
Adrenergic Gene Polymorphisms and Cardiovascular Risk in the Nhlbi-Sponsored Women'S Ischemia Syndrome Evaluation
2008
Genetic Predictors of Glucocorticoid-Induced Hypertension in Children With Acute Lymphoblastic Leukemia
Pharmacogenetics and Genomics
2008
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.
2008
A Genome-Wide Scan for Common Genetic Variants With a Large Influence On Warfarin Maintenance Dose
Blood
2008
Association of Beta(1)-Adrenergic Receptor Genetic Polymorphism With Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Artery Disease
Archives of Internal Medicine
2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
2008
Beta-Blocker Pharmacogenetics in Heart Failure
Heart Failure Reviews
2008
Warfarin: An Old Drug But Still Interesting
Pharmacotherapy
2008
Use of Pharmacogenetic and Clinical Factors To Predict the Therapeutic Dose of Warfarin
Clinical Pharmacology & Therapeutics
2008
Dna Variations in Voltage-Gated Calcium Channel Beta 2 Subunit (Cacnb2) Gene, Functional Consequences, and Association With Adverse Cardiovascular Outcomes in the International Verapamil Sr-Trandolapril Study-Genetic Substudy
2008
Simplified Method for Determination of Clarithromycin in Human Plasma Using Protein Precipitation in a 96-Well Format and Liquid Chromatography-Tandem Mass Spectrometry
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
2008
A summer research training program to foster PharmD students' interest in research.
American Journal of Pharmaceutical Education
2008
Ethnic Differences in Cardiovascular Drug Response Potential Contribution of Pharmacogenetics
2008
Cyp4F2 Genetic Variant Alters Required Warfarin Dose
Blood
2007
Synergistic Polymorphisms of Beta1- and Alpha2c-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction Response to Beta-Blocker Therapy in Heart Failure
Pharmacogenetics and Genomics
2007
KCNMB1 Genotype Influences Response to Verapamil SR and Adverse Outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)
Pharmacogenetics and Genomics
2007
Factors Influencing Blood Pressure Response to Trandolapril Add-On Therapy in Patients Taking Verapamil SR (from the International Verapamil SR/Trandolapril Study [NVEST])
American Journal of Cardiology
2007
A Beta2-Adrenoceptor Haplotype is Associated with the Increased Risk for Death and Heart Transplantation in Heart Failure Patients
American Journal of Cardiology
2007
Association of Diurnal Blood Pressure Pattern with Risk for Hospitalization or Death in Men with Heart Failure
Journal of Cardiac Failure
2007
Pharmacogenetics of Beta-Blockers
Pharmacotherapy
2007
Epistatic Control of Human Obesity as Revealed by Linkage Disequilibrium Mapping: a Report from the NHLBI-Sponsored WISE Study
Current Genomics
2007
Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events
Clinical Pharmacology & Therapeutics
2007
Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness
Molecular Diagnosis and Therapy
2007
Single Nucleotide Polymorphism Discovery and Haplotype Analysis of Ca2+ -Dependent K+ Channel Beta-1 Subunit
Pharmacogenetics and Genomics
2007
Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil
Clinical Pharmacology & Therapeutics
2007
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
Clinical Pharmacology & Therapeutics
2007
Modeling Sequence-Sequence Interactions of Drug Response
2007
PharmGKB Submission Update: IX. ADRB1 Gene Summary
Pharmacological Reviews
2006
Influence of Coagulation Factor, Vitamin K Epoxide Reductase Complex Subunit 1 and Cytochrome P450 2C9 Gene Polymorphisms on Warfarin Dose Requirements
Clinical Pharmacology & Therapeutics
2006
Sustained Restoration of Autonomic Balance with Long- but not Short-Acting Metoprolol in Patients with Heart Failure
Journal of Cardiac Failure
2006
A Bivariate Functional Mapping Model for Identifying Haplotypes that Control Drug Response for Systolic and Diastolic Blood Pressures
Pacific Symposium on Biocomputing
2006
Highly Variable mRNA Expression and Splicing of L-Type Voltage-Dependent Calcium Channel Alpha Subunit 1c (CACNA1C) in Human Heart Tissues
Pharmacogenetics and Genomics
2006
Pharmacogenomics: Challenges and Opportunities
Annals of Internal Medicine
2006
Discordant Beta-Blocker Effects on Clinic, Ambulatory, Resting and Exercise Hemodynamics in Patients with Hypertension
Pharmacotherapy
2006
Genetic Determinants of -Blocker Response: Influence of Phenotype and Pharmacokinetics on Drug Target Pharmacogenetics
The Pharmacogenomics Journal
2006
Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
Expert Opinion on Pharmacotherapy
2005
Hypertension pharmacogenomics: current status and future directions.
Current Opinion in Molecular Therapeutics
2005
Beta-Adrenergic Receptor Polymorphisms and Responses During the Titration of Metoprolol CR/XL in Patients with Heart Failure
Clinical Pharmacology & Therapeutics
2005
Sequencing Drug Response with HapMap
The Pharmacogenomics Journal
2005
Use of pharmacogenetics in clinical medicine: hype or hope?
Personalized Medicine
2005
Cardiovascular pharmacogenomics.
2005
A Pharmacodynamic Model of the Effects of Controlled-Onset Extended-Release Verapamil on 24 Hour Ambulatory Blood Pressure
International Journal of Clinical Pharmacology and Therapeutics
2005
Beta1-Adrenergic Receptor Polymorphisms and Left Ventricular Remodeling Changes in Response to Beta-Blocker Therapy
Pharmacogenetics and Genomics
2005
Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study
International Journal of Obesity
2004
Pharmacokinetics and CYP2D6 Genotypes do not Predict Metoprolol Adverse Events or Efficacy in Hypertension
Clinical Pharmacology & Therapeutics
2004
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
2004
Sequencing Complex Diseases with HapMap
Genetics
2004
Comparison of Cytochrome P450 2C9 Genotyping Methods and Implications for the Clinical Laboratory
Pharmacotherapy
2004
The Influence of Sex and Race on Pharmacodynamics Response to Dobutamine During Dobutamine Stress Echocardiography
American Journal of Cardiology
2004
A Statistical Model for Functional Mapping of Quantitative Trait Loci Regulating Drug Response
The Pharmacogenomics Journal
2004
Caution with 1-Adrenergic Receptor Genotyping
Clinical Pharmacology & Therapeutics
2003
A Haplotype-Based Algorithm for Multilocus Linkage Disequilibrium Mapping of Quantitative Trait Loci with Epistasis
2003
Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.
Pharmacogenetics and Genomics
2003
The evolving role of nesiritide in advanced or decompensated heart failure.
Pharmacotherapy
2003
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Clinical Pharmacology & Therapeutics
2003
Pharmacogenetics: potential for individualized drug therapy through genetics.
Trends in genetics
2002
Pharmacogenetics of cardiovascular drugs.
Briefings in Functional Genomics & Proteomics
2002
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics.
Pharmaceutical Research
2002
Dobutamine Pharmacodynamics During Dobutamine Stress Echocardiography and the Impact of Beta-Blocker Withdrawal: A Report from the Women’s Ischemic Syndrome Evaluation Study
Pharmacotherapy
2002
Pharmacogenomics: A Scientific Revolution in Pharmaceutical Sciences and Pharmacy Practice. Report of the 2001/02 Academic Affairs Committee
American Journal of Pharmaceutical Education
2002
Pharmacogenetics, Pharmacogenomics and Cardiovascular Therapeutics: The Way Forward
American Journal of Cardiovascular Drugs
2002
Collection of Genomic DNA by Noninvasive Mouthwash Method for Use in Pharmacogenetic Studies
Pharmacotherapy
2002
Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity.
Trends in Molecular Medicine
2001
The Effect of Gut Metabolism on Tacrolimus Bioavailability in Renal Transplant Recipients
Transplantation
2001
Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia
American Journal of Cardiology
2001
Determination of Human Beta2-Adrenoceptor Haplotypes by Denaturation Selective Amplification and Subtractive Genotyping
American Journal of Pharmacogenomics
2001
Pharmacogenomics: The Inherited Basis for Inter-Individual Differences in Drug Response
Annual Review of Genomics and Human Genetics
2001
Drug target pharmacogenomics: an overview.
American Journal of Pharmacogenomics
2001
INVEST Substudies: Design and Patient Characteristics
Clinical Cardiology
2000
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Journal of Pharmacology and Experimental Therapeutics
2000
Sequencing of Beta2-Adrenoceptor Gene PCR Products Using Taq BigDye Terminator Chemistry Results in Inaccurate Base-Calling
Biotechniques
2000
Effects of COER-Verapamil on Circadian Pattern of Forearm Vascular Resistance and Blood Pressure
2000
Importance of Beta2 Adrenergic Receptor Genotype, Gender and Race on Albuterol-Evoked Bronchodilation in Asthmatics
Pulmonary Pharmacology & Therapeutics
2000
Simple Method for Determination of Terbutaline Plasma Concentration by High Performance Liquid Chromatography
Journal of Chromatography B: Biomedical Sciences and Applications
2000
Predictability of the Effects of Race or Ethnicity on Pharmacokinetics of Drugs (Invited Review)
International Journal of Clinical Pharmacology and Therapeutics
2000
Gender Differences in Labetalol Kinetics: Importance of Determining Stereoisomer Kinetics for Racemic Drugs
Pharmacotherapy
1999
Intranasal DDAVP-Induced Increases in Plasma Von Willebrand Factor Alter the Pharmacokinetics of High-Purity Factor VIII Concentrates in Severe Hemophilia A Patients
Hemophilia
1999
Effects of Gender and Race on Albuterol Pharmacokinetics
Pharmacotherapy
1999
Impact of Genetic Polymorphisms of the Beta2-Adrenergic Receptor on Albuterol Bronchodilator Pharmacodynamics
Clinical Pharmacology & Therapeutics
1998
The Role of Endothelin-1 in Heart Failure and Hypertension
Pharmacotherapy
1997
Differences Between Blacks and Whites in Plasma Protein Binding of Drugs
1997
Influence of Race or Ethnicity on Pharmacokinetics of Drugs
Journal of Pharmaceutical Sciences
1996
Metoprolol Metabolism Via Cytochrome P450 2D6 in Ethnic Populations
Drug Metabolism and Disposition
1996
Racial Differences in Propranolol Enantiomer Kinetics Following Simultaneous IV and Oral Administration
British Journal of Clinical Pharmacology
1995
Racial Differences in Sensitivity to the Negative Chronotropic Effects of Propranolol in Healthy Males
Clinical Pharmacology & Therapeutics
1995
Influence of Metabolites on Protein Binding of Verapamil Enantiomers
British Journal of Clinical Pharmacology
1995
Racial Differences in Beta-Adrenoceptor-Mediated Responsiveness
Journal of Cardiovascular Pharmacology
1995
Metoprolol Minimizes Nighttime Blood Pressure Dip in Hypertensive Black Males
American Journal of Hypertension
1995
Lymphocyte Beta2-Receptor Activity, Metoprolol Kinetics and Response to Metoprolol in Hypertensive Black Men
Pharmacotherapy
1993
Direct High Performance Liquid Chromatographic Determination in Urine of the Enantiomers of Propranolol and its Major Basic Metabolite 4-Hydroxypropranolol
Journal of Chromatography a
1993
Differences in Apparent Sensitivities of Chronotropy and Inotropy to Propranolol
Hellenic Journal of Cardiology
1993
Racial Differences in Lymphocyte Beta-Receptor Sensitivity to Propranolol
Life Sciences
1992
Racial Differences in Propranolol Pharmacokinetics
Clinical Pharmacology & Therapeutics
1991
Diastolic Dysfunction in Congestive Heart Failure
Clinical Pharmacy
1990
Use of Beta-Adrenergic Blocking Agents in Congestive Heart Failure
Clinical Pharmacy
1990
Comparison of Single Dose and Steady State Nadolol Plasma Concentrations
Pharmaceutical Research
1990
Comparison of Hypersensitivity to Adrenergic Stimulation After Abrupt Withdrawal of Propranolol and Nadolol: Influence of Half-Life Differences
American Heart Journal
1989
Biphasic Pattern of Hypersensitivity Following Acute Propranolol Withdrawal in Normal Subjects
Life Sciences
1989
Drug- or Hormone-Induced Adaptation: Model of Adrenergic Hypersensitivity
Journal of Pharmacokinetics and Pharmacodynamics
1987
Lovastatin: A New Cholesterol Lowering Agent
Pharmacotherapy
1986
Dose- and Time-Dependent Binding and Kinetics of Pindolol in Patients with Congestive Heart Failure
1986
Management of Pediatric Patients with Bronchiolitis in the Emergency Department
Journal of Quality Assurance
1985
Prophylactic Antibiotics in Plastic Surgery
Journal of Quality Assurance
1985
Management of Bronchiolitis
Clinical Pharmacy

Grants

September 2018ACTIVE
Sparking Advancements in Genomic Medicine?
NATL INST OF HLTH NHGRI · Principal Investigator
January 2018ACTIVE
Training Program for Applied Research and Development in Genomic Medicine
NATL INST OF HLTH NHGRI · Principal Investigator
July 2016ACTIVE
A stem cell tactic to promote personalized medicine
NATL INST OF HLTH NIGMS · Project Manager
July 2016 – June 2018
A Stem Cell Tactic to Promote Personalized Medicine in Hypertension
AMER HEART ASSOCIATION ·
October 2015 – March 2019
OneFlorida Clinical Research Consortium Phase II
PATIENT-CENTERED OUTCOMES RES INST · Project Manager
July 2014 – December 2015
Using Different OMICS for the Identification of Novel Biomarkers of Blood Pressure Response to Antihypertensive Drugs
AMER HEART ASSOCIATION · Principal Investigator
June 2013 – September 2018
Genomic Medicine Implementation: The Personalized Medicine Program
NATL INST OF HLTH NHGRI · Principal Investigator
March 2011 – February 2016
Secondary Prevention of Subcortical Stroke Prevention
NATL INST OF HLTH NINDS · Principal Investigator
August 2010 – July 2017
PEAR
NATL INST OF HLTH NIGMS · Principal Investigator
July 2007 – August 2016
Clinical and Translational Science Institute
UF RESEARCH FOU · Project Manager

Patents

Published May 2009
Use of Genetic Determinants in Cardiovascular Risk Assessment
US 2010-0021903-A1
Published August 2007
B-Blocker Pharmacogenetics in Heart Failure
US-2008-0269346-A1
Published July 2003
Beta-Adrenoceptor Genetic Polymorphisms and Obesity
US-2004-0033524
Published February 2002
Methods of Diagnosing Obesity and Products Related Thereto
US-2002-0187491

Education

1987-1989
Postdoctoral Fellowship in Pharmacokinetics/Clinical Pharmacology
The Ohio State University
1987
Pharm.D.
The University of Texas at Austin and The University of Texas Health Science Center at San Antonio
1985
B.S.
The Ohio State University